INmune Bio, Inc. (NASDAQ: INMB) reported Q1 EPS of ($0.43), $0.06 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $50 thousand.

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.